Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
56
GNOM Quote, Financials, Valuation and Earnings
Last price:
$47.16
Seasonality move
:
-15.59%
Day range:
$47.13 - $47.43
52-week range:
$27.20 - $48.09
Dividend yield:
0.07%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.6K
Avg. volume:
11.8K
1-year change:
18.27%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
$47.20 | -- | -- | -- | $0.03 | 0.07% | -- |
|
AGNG
Global X Aging Population ETF
|
$36.50 | -- | -- | -- | $0.14 | 0.79% | -- |
|
HEAL
Global X HealthTech ETF
|
$29.76 | -- | -- | -- | $0.02 | 0.08% | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
$32.51 | -- | -- | -- | $0.32 | 0.98% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$26.78 | -- | -- | -- | $0.16 | 1.15% | -- |
|
PPH
VanEck Pharmaceutical ETF
|
$104.43 | -- | -- | -- | $0.39 | 1.85% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 1.886 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.484 | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | 1.781 | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | 1.095 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 0.936 | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | 0.233 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- | -- |
|
IBRN
iShares Neuroscience and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- | -- |
Global X Genomics & Biotechnology ETF vs. Competitors
-
Which has Higher Returns GNOM or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Aging Population ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is GNOM or AGNG More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.286, which suggesting that the stock is 28.563% more volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.722%.
-
Which is a Better Dividend Stock GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. Global X Aging Population ETF offers a yield of 0.79% to investors and pays a quarterly dividend of $0.14 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or AGNG?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns GNOM or HEAL?
Global X HealthTech ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X HealthTech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- HEALGlobal X HealthTech ETF-- -- -- -
What do Analysts Say About GNOM or HEAL?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X HealthTech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X HealthTech ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X HealthTech ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 HEALGlobal X HealthTech ETF0 0 0 -
Is GNOM or HEAL More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.286, which suggesting that the stock is 28.563% more volatile than S&P 500. In comparison Global X HealthTech ETF has a beta of 1.219, suggesting its more volatile than the S&P 500 by 21.903%.
-
Which is a Better Dividend Stock GNOM or HEAL?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. Global X HealthTech ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.02 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X HealthTech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or HEAL?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X HealthTech ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X HealthTech ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X HealthTech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X HealthTech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- HEALGlobal X HealthTech ETF-- -- -- --
-
Which has Higher Returns GNOM or IBRN?
iShares Neuroscience and Healthcare ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat iShares Neuroscience and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- -
What do Analysts Say About GNOM or IBRN?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Neuroscience and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than iShares Neuroscience and Healthcare ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than iShares Neuroscience and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 IBRNiShares Neuroscience and Healthcare ETF0 0 0 -
Is GNOM or IBRN More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.286, which suggesting that the stock is 28.563% more volatile than S&P 500. In comparison iShares Neuroscience and Healthcare ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNOM or IBRN?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. iShares Neuroscience and Healthcare ETF offers a yield of 0.98% to investors and pays a quarterly dividend of $0.32 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. iShares Neuroscience and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or IBRN?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than iShares Neuroscience and Healthcare ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than iShares Neuroscience and Healthcare ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while iShares Neuroscience and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for iShares Neuroscience and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- IBRNiShares Neuroscience and Healthcare ETF-- -- -- --
-
Which has Higher Returns GNOM or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About GNOM or IDNA?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is GNOM or IDNA More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.286, which suggesting that the stock is 28.563% more volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.579%.
-
Which is a Better Dividend Stock GNOM or IDNA?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. iShares Genomics Immunology and Healthcare ETF offers a yield of 1.15% to investors and pays a quarterly dividend of $0.16 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or IDNA?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
-
Which has Higher Returns GNOM or PPH?
VanEck Pharmaceutical ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat VanEck Pharmaceutical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- PPHVanEck Pharmaceutical ETF-- -- -- -
What do Analysts Say About GNOM or PPH?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Pharmaceutical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than VanEck Pharmaceutical ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than VanEck Pharmaceutical ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 PPHVanEck Pharmaceutical ETF0 0 0 -
Is GNOM or PPH More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.286, which suggesting that the stock is 28.563% more volatile than S&P 500. In comparison VanEck Pharmaceutical ETF has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.102%.
-
Which is a Better Dividend Stock GNOM or PPH?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.07%. VanEck Pharmaceutical ETF offers a yield of 1.85% to investors and pays a quarterly dividend of $0.39 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. VanEck Pharmaceutical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or PPH?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than VanEck Pharmaceutical ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than VanEck Pharmaceutical ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while VanEck Pharmaceutical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for VanEck Pharmaceutical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- PPHVanEck Pharmaceutical ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
